Tyra Biosciences Q1 net loss $14.8M; cash $292.5M; IND filings on track for 2022

Tyra Biosciences, Inc.

2023-Q1 EPS reported -$0.36

Net loss of $14.8M in Q1 2022 vs $4.2M in Q1 2021, driven by higher R&D and G&A expenses.
R&D expense $9.6M (up from $3.5M); G&A expense $5.2M (up from $0.7M).
Cash and equivalents $292.5M as of March 31, 2022, supporting pipeline into clinical stage.
IND for TYRA-300 (FGFR3 inhibitor) expected mid-2022; TYRA-200 (FGFR2) IND in H2 2022.
Pipeline includes programs in achondroplasia, RET, and FGFR4-driven cancers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.